Cellectis (NASDAQ:CLLS) Lifted to “Hold” at StockNews.com

Cellectis (NASDAQ:CLLSGet Rating) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Separately, Citigroup boosted their price objective on Cellectis from $34.00 to $36.00 in a research report on Thursday, August 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Cellectis has a consensus rating of “Hold” and a consensus price target of $15.17.

Cellectis Stock Down 2.7 %

Shares of NASDAQ CLLS opened at $2.19 on Thursday. The business has a 50-day moving average of $2.55 and a 200-day moving average of $2.94. The firm has a market capitalization of $99.79 million, a price-to-earnings ratio of -0.95 and a beta of 2.01. Cellectis has a 12 month low of $2.00 and a 12 month high of $9.81. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On Cellectis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Envestnet Asset Management Inc. raised its holdings in Cellectis by 19.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 20,501 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,305 shares during the period. State Street Corp grew its holdings in shares of Cellectis by 3.7% during the first quarter. State Street Corp now owns 119,561 shares of the biotechnology company’s stock worth $543,000 after buying an additional 4,297 shares during the last quarter. Princeton Capital Management LLC purchased a new stake in Cellectis in the 1st quarter valued at approximately $50,000. Two Sigma Investments LP acquired a new position in shares of Cellectis during the 3rd quarter worth approximately $30,000. Finally, Capital Wealth Alliance LLC purchased a new stake in Cellectis in the 2nd quarter worth approximately $680,000. Hedge funds and other institutional investors own 23.83% of the company’s stock.

About Cellectis

(Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Featured Stories

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.